ClinicalTrials.gg
CompletedNCT05626530Updated Oct 26, 2026

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

A Phase 4 interventional study of Letermovir in Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients and Neutropenia, sponsored by Tufts Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Tufts Medical Center · Phase 4, Interventional, and Prevention

How we know

Updated Oct 26, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.

Enrollment
14th of 17
21 · median 80
Started
2023
with 3 others
Phase 4
4 of 17
2 open now
Registered
7th of 17
by date
Lead sponsor
2 of 17
Tufts Medical Center

Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 14th largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 4, and was the 7th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About letermovir

letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letermovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient.

This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.

Read the detailed description

This study will enroll solid organ transplant recipients who develop cytomegalovirus infection and disease who have been treated. At the time of finishing treatment, if the clinician feels that secondary prophylaxis is indicated, they will be enrolled to receive Letermovir 480 mg orally once a day for 60 days. CMV specific T cell assays will be obtained at the initiation of secondary prophylaxis and at the discontinuation of secondary prophylaxis. Patients will be followed for 4 months following discontinuation of secondary prophylaxis to see if they relapse.

03

Conditions studied

  • Cytomegalovirus Infections
  • Infection in Solid Organ Transplant Recipients
  • Neutropenia
  • Antiviral Toxicity

Keywords

  • Cytomegalovirus infection
  • Letermovir
  • Secondary prophylaxis
  • T cell immunity
  • neutropenia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (> 18 years old) solid organ transplant recipients (heart, kidney or liver patients) recovering from treated CMV disease in whom the clinician deems that the patient need secondary prophylaxis and in whom written is obtained.
  2. Patient able to participate with follow up for 6 months
  3. Not enrolled in competing clinical trials

Exclusion criteria

Exclusion Criteria:

  1. Patients with less than 10 ml per min at time of enrollment
  2. to letermovir or has a CMV isolate which is known to be resistant to letermovir based on prior testing
  3. On CVVH or renal dialysis at the time of enrollment
  4. Has Class C severe hepatic insufficiency at screening.
  5. Has both moderate hepatic insufficiency AND moderate to severe renal insufficiency at screening.

    Note: Moderate hepatic insufficiency is defined as Child Pugh Class B (Appendix 8); moderate to severe renal insufficiency is defined as CrCl \<50 mL/min, as calculated by the Cockcroft-Gault equation.

  6. Has a history of ≤5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy.
  7. Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through at least 90 days following cessation of study therapy.
  8. Is expecting to donate eggs or sperm starting from the time of consent through at least 90 days following cessation of study therapy.
  9. Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or put the participant at undue risk, as judged by the investigator, such that it is not in the best interest of the participant to participate in this study.
  10. Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the 6 months) of drug or alcohol abuse or dependence.

    Note: Participants with a history of marijuana use which is not deemed excessive by an investigator or does not interfere with the participant's daily function may participate in the study.

  11. Is currently participating or has participated in a study with an unapproved compound or device within 28 days, or 5× half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study. Participants previously treated with an investigational monoclonal antibody will be eligible to participate after a 150-day .
  12. Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent that is not approved or is planning to participate in a study of a CMV vaccine or another unapproved CMV investigational agent during the course of this study.

    -

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Other
    single arm

    This is an open label single arm study

    Drug: Letermovir

Interventions

  • Open label 480 mg given daily for 60 days

    Also known as: Active drug

06

What researchers measure

Primary outcomes

  1. Rate of Relapse after prophylaxis

    Proportion of patients with relapsing CMV disease up to 6 months after starting drug

    Time frame: 6 months after starting intervention

Secondary outcomes

  1. Opportunistic infection

    Rate of opportunistic infections or other infectious outcomes in the letermovir arm.

    Time frame: 6 months after starting

  2. Adverse events associated with taking letermovir

    Tolerability and compliance of patients taking letermovir in terms of adverse events

    Time frame: 6 months after starting

  3. Neutropenia

    Duration and nadir of neutropenia in the letermovir group

    Time frame: 6 months after starting intervention

  4. Rejection

    Rate of rejection at 6 months after starting secondary prophylaxis in the letermovir arm.

    Time frame: 6 months

  5. T cell function

    Proportion of patients who have demonstrated CMV specific T cell immunity at start of letermovir secondary prophylaxis will be compared to the proportion who have CMV specific T cell function at the discontinuation of prophylaxis

    Time frame: 6 months after starting intervention

07

Study locations

1 site
  • Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases
    Boston, Massachusetts 02111, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2023 to primary completion in Mar 2026, 36 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2025 → Mar 2026 and completion Dec 2025 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2022
First posted
Nov 23, 2022
StartActual
Feb 2, 2023
Primary completionActual
Mar 1, 2026was Dec 2025
CompletionActual
Mar 1, 2026was Dec 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Primary completion
Dec 15, 2025→Mar 1, 2026 (actual)
Oct 26, 2026
Study completion
Dec 15, 2025→Mar 1, 2026 (actual)
Oct 26, 2026
Enrollment
25 (estimated)→21 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Completed
    Primary completion Dec 15, 2025→Mar 1, 2026 (now actual)
    Study completion Dec 15, 2025→Mar 1, 2026 (now actual)
    Enrollment 25 (estimated)→21 (actual)
    + 6 other changes: verification date, oversight details, criteria formatting, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05626530
Responsible party
Sponsor
First posted
Nov 23, 2022
Start date
Feb 2, 2023
Primary completion
Mar 1, 2026
Completion
Mar 1, 2026
Last update
Oct 26, 2026

Study contacts

Jennifer K Chow, MD, MS
principal investigator · Tufts Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion